Recombinant BCG-Prime and DNA-Boost Immunization Confers Mice with Enhanced Protection against Mycobacterium kansasii
| Autor: | Mitsuo Honda, Satoshi Hayakawa, Takahiro Namiki, Satoru Mizuno, Kazuhiro Matsuo, Shihoko Komine-Aizawa |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Immunology
recombinant BCG CD8+ T Cells Antigen Immunity Drug Discovery Cytotoxic T cell Medicine Pharmacology (medical) Pharmacology Mycobacterium kansasii biology business.industry CD4+ T Cells bacterial infections and mycoses biology.organism_classification Virology Vaccination Infectious Diseases Immunization bacteria Nontuberculous mycobacteria business Mycobacterium |
| Zdroj: | Vaccines Volume 9 Issue 11 Vaccines, Vol 9, Iss 1260, p 1260 (2021) |
| ISSN: | 2076-393X |
| DOI: | 10.3390/vaccines9111260 |
| Popis: | The incidence of infections with nontuberculous mycobacteria (NTM) has been increasing worldwide. The emergence of multidrug-resistant NTM is a serious clinical concern, and a vaccine for NTM has not yet been developed. We previously developed a new recombinant Bacillus Calmette–Guérin (rBCG) vaccine encoding the antigen 85B (Ag85B) protein of Mycobacterium kansasii—termed rBCG-Mkan85B—which was used together with a booster immunization with plasmid DNA expressing the same M. kansasii Ag85B gene (DNA-Mkan85B). We reported that rBCG-Mkan85B/DNA-Mkan85B prime–boost immunization elicited various NTM strain-specific CD4+ and CD8+ T cells and induced Mycobacterium tuberculosis-specific immunity. In this study, to investigate the protective effect against M. kansasii infection, we challenged mice vaccinated with a rBCG-Mkan85B or rBCG-Mkan85B/DNA-Mkan85B prime–boost strategy with virulent M. kansasii. Although BCG and rBCG-Mkan85B immunization each suppressed the growth of M. kansasii in the mouse lungs, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination reduced the bacterial burden more significantly. Moreover, the rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination induced antigen-specific CD4+ and CD8+ T cells. Our data suggest that rBCG-Mkan85B/DNA-Mkan85B prime–boost vaccination effectively enhances antigen-specific T cells. Our novel rBCG could be a potential alternative to clinical BCG for preventing various NTM infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|